Zilixir Biotech is a biotechnology startup that aims to revolutionize life sciences exploration. With the groundbreaking SWORD™ protein design technology, the company is pushing the boundaries of protein design, enabling new possibilities for human exploration within the field. This innovative technology encompasses binding pockets, new drug skeleton design, activity prediction, and ADME/T prediction, demonstrating significant advancements in these critical areas.
The company, founded in 2021, has recently secured a noteworthy CNY100.00M Series A investment, which took place on 25 May 2023. The investment was led by prominent venture capital firms including Life Capital, Q Ventures, Qingdao Qingchi Venture Capital, Hongfeng Investment Management, and Huimei Capital.
With a compelling slogan "Unleashing potential with groundbreaking protein design technology for complex life sciences exploration", Zilixir Biotech is strategically positioned to make a substantial impact in the biotechnology industry with its innovative approach and strong backing from key investors.
No recent news or press coverage available for Zilixir Biotech.